acut
respiratori
tract
infect
major
caus
respiratori
morbid
mortal
pediatr
patient
worldwid
howev
accur
viral
immunolog
marker
predict
clinic
outcom
patient
popul
still
lack
droplet
digit
pcr
assay
influenza
respiratori
syncyti
viru
rsv
design
perform
respiratori
sampl
patient
influenza
viru
infect
sampl
patient
rsv
infect
sampl
patient
hematolog
malign
solid
tumor
sickl
cell
diseas
includ
clinic
inform
institut
medic
record
review
assess
diseas
sever
sampl
patient
fever
respiratori
symptom
significantli
higher
viral
load
asymptomat
patient
sampl
patient
influenza
viru
rsv
infect
collect
present
significantli
higher
viral
load
collect
patient
complet
cours
oseltamivir
ribavirin
respect
rsv
load
correl
posit
clinic
symptom
patient
year
age
wherea
influenza
viral
load
associ
clinic
symptom
irrespect
age
patient
receiv
antivir
influenza
rsv
signific
reduct
viral
load
complet
therapi
digit
pcr
offer
effect
method
monitor
efficaci
antivir
treatment
respiratori
tract
infect
immunocompromis
host
acut
respiratori
tract
infect
lead
caus
morbid
mortal
infant
children
worldwid
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
adenoviru
picornaviru
play
import
role
etiolog
respiratori
diseas
immunocompet
immunocompromis
patient
especi
undergo
myelosuppress
hematopoiet
cell
transplant
plo
consider
advanc
made
predict
clinic
outcom
sever
system
viral
infect
eg
hiv
measur
viral
load
marker
immun
activ
becom
part
standard
clinic
care
unfortun
case
influenza
rsv
viral
respiratori
infect
despit
enorm
global
health
impact
viral
respiratori
infect
accur
viral
immun
marker
predict
clinic
outcom
patient
still
lack
sever
method
use
precis
correl
viral
copi
number
diseas
sever
molecular
quantit
assay
suggest
detect
monitor
clinic
viral
respiratori
diseas
particularli
immunosuppress
pediatr
patient
howev
result
conflict
continu
lack
clinic
test
accur
measur
viral
load
furthermor
respiratori
infect
patient
associ
prolong
viral
shed
concern
emerg
antivir
resist
viral
infect
treatabl
quantit
determin
viral
load
may
provid
import
tool
directli
evalu
effici
antivir
therapi
determin
chang
therapi
necessari
assess
need
isol
protect
transmiss
highli
suscept
host
problem
highlight
import
potenti
valu
develop
assay
absolut
precis
reliabl
quantit
viral
detect
improv
accuraci
clinic
decis
make
immunocompromis
children
viral
respiratori
infect
viral
load
commonli
determin
quantif
viral
genom
fragment
quantit
determin
realtim
pcr
indirect
provid
rel
quantif
viral
load
howev
precis
assay
limit
natur
cycl
threshold
ct
determin
result
valu
rel
standard
deviat
exceed
addit
assay
workflow
design
complic
need
quantit
calibr
introduc
error
risk
requir
consist
suppli
wellcharacter
commut
refer
materi
latter
particularli
difficult
obtain
less
commonli
quantifi
virus
gener
particularli
rna
virus
studi
mark
variat
assay
perform
characterist
materi
use
calibr
describ
implement
intern
standard
made
avail
world
health
organ
led
reduct
problem
howev
standard
avail
limit
number
pathogen
vari
time
digit
pcr
dpcr
pcr
method
detect
quantit
nucleic
acid
dpcr
offer
sever
advantag
real
time
method
digit
pcr
differ
realtim
method
way
sampl
target
measur
divid
reaction
multipl
smaller
endpoint
reaction
allow
direct
absolut
quantif
target
dpcr
method
depend
calibr
curv
less
subject
enzym
inhibit
employ
endpoint
amplif
robust
presenc
viral
sequenc
heterogen
show
less
suscept
mismatch
primersprob
patient
viral
sequenc
missmatch
like
caus
falseneg
result
underquantit
use
qprc
compar
dpcr
particularli
import
rna
virus
high
mutat
rate
need
week
escap
immun
respons
produc
drugresist
mutant
final
clinic
result
gener
dpcr
precis
reliabl
reproduc
realtim
pcr
therebi
highlight
potenti
diagnost
prognost
predict
util
although
dpcr
previous
use
quantit
detect
system
virus
use
limit
local
viral
infect
respiratori
tract
studi
analyt
clinic
valid
two
dpcr
assay
quantit
detect
influenza
viru
rsv
pediatr
patient
hematolog
malign
solid
tumor
sicklecel
diseas
scd
viral
load
also
correl
clinic
symptom
provid
one
first
demonstr
technolog
monitor
therapeut
respons
antivir
agent
studi
approv
st
jude
institut
review
board
sampl
fulli
anonym
initi
studi
irb
committe
waiv
requir
inform
consent
st
jude
quaternari
referr
center
pediatr
patient
cancer
includ
requir
hematopoiet
cell
transplant
hct
patient
scd
pediatr
patient
hematolog
malign
solid
tumor
scd
consecut
respiratori
sampl
posit
influenza
viru
rsv
retrospect
identifi
result
routin
clinic
test
qualit
pcr
qpcr
filmarray
biofir
diagnost
st
jude
children
research
hospit
st
jude
memphi
tn
medic
record
review
extract
inform
age
gender
race
primari
diagnosi
date
infect
influenza
rsv
symptom
clinic
cours
laboratori
result
support
antivir
treatment
lower
respiratori
tract
infect
lrti
defin
crackl
hypoxia
tachypnea
apnea
andor
radiograph
evid
pneumonia
infiltr
consolid
institut
infect
control
prevent
polici
mandat
patient
either
influenza
rsv
infect
neg
test
order
discontinu
isol
precaut
result
mani
patient
get
subsequ
test
even
absenc
symptom
patient
consid
asymptomat
symptom
time
sampl
collect
studi
approv
st
jude
institut
review
board
remnant
sampl
nasopharyng
wash
obtain
routin
care
use
studi
wash
perform
use
normal
salin
immedi
transport
clinic
virolog
laboratori
ice
store
test
within
hour
collect
sampl
remain
clinic
test
store
qualiti
assur
use
evalu
digit
pcr
dpcr
assay
influenza
perform
use
raindrop
digit
pcr
system
raindanc
technolog
viror
assay
kit
ingenetix
viral
rna
stock
gener
vitro
synthesi
purchas
ingenetix
use
analyt
valid
assay
along
viral
stock
materi
gener
atcc
quantifi
atcc
use
dpcr
plaqueform
unit
tissu
cultur
infect
dose
zeptometrix
assay
rsv
also
design
raindrop
digit
pcr
system
primerprob
previous
design
qpcr
synthet
viral
rna
stock
analyt
valid
rsv
assay
purchas
biosynthesi
inc
along
addit
viral
stock
materi
atcc
zeptometrix
thaw
room
temperatur
nucleic
acid
purifi
previous
frozen
sampl
use
specif
protocol
nuclisen
easymag
nucleic
acid
extractor
store
intern
control
intyp
icrna
qiagen
inc
ad
extract
sampl
read
use
vic
channel
dpcr
dpcr
conduct
use
raindrop
digit
pcr
system
viror
assay
kit
ingenetix
use
influenza
b
assay
wherea
rsv
assay
primerprob
adapt
previous
design
laboratorydevelop
qrtpcr
assay
assay
volum
use
viru
sampl
standard
qpcr
protocol
ingenetix
quantabio
use
master
mix
cycl
condit
cycl
reaction
transfer
raindrop
reader
data
analyz
use
raindrop
analyst
ii
softwar
result
copi
per
reaction
convert
log
copi
per
millilit
origin
patient
sampl
preextract
valid
influenza
rsv
includ
multipl
lot
number
reagent
span
sever
month
allow
run
variabl
assess
sampl
qiagen
ipc
ad
prior
extract
control
inhibit
rang
copiesml
cross
reactiv
three
assay
test
use
zeptometrix
respiratori
panel
valid
also
includ
determin
limit
detect
posit
cutoff
valu
linear
within
run
variabl
limit
quantit
limit
blank
lob
defin
cutoff
templat
control
consid
baselin
valu
elimin
fals
posit
result
due
background
nois
lod
initi
calcul
determin
lowest
nonzero
concentr
replic
gave
posit
result
loq
base
percent
cv
linear
run
lowest
level
cv
calcul
lod
loq
lower
lob
clinic
sampl
use
valid
run
blind
descript
statist
analys
present
proport
categor
data
mean
standard
deviat
continu
data
statist
analysi
perform
use
chisquar
test
fisher
exact
test
appropri
categor
data
student
ttest
continu
variabl
account
differ
number
sampl
per
patient
mix
linear
regress
model
use
determin
associ
viral
load
clinic
characterist
presenc
symptom
number
symptom
individu
symptom
fever
cough
nasal
congest
fig
lymphocyt
count
fig
presenc
absenc
coinfect
number
addit
virus
fig
random
variabl
patient
identifi
similar
mix
linear
regress
model
approach
use
determin
associ
lymphocyt
count
presenc
symptom
logist
regress
use
initi
viral
load
upon
clinic
present
use
assess
correl
viral
load
clinic
complic
univari
multivari
analysi
pair
ttest
use
compar
sampl
treatment
pvalu
consid
statist
signific
analyt
specif
influenza
posit
predict
valu
neg
predict
valu
tabl
plot
linear
influenza
r
valu
fig
within
run
variat
rang
cv
cv
high
extern
control
cv
cv
low
extern
control
run
variat
cv
high
control
cv
low
control
tabl
influenza
limit
detect
limit
quantit
cutoff
posit
coincid
log
copiesml
tabl
analyt
specif
influenza
b
posit
predict
valu
neg
predict
valu
tabl
plot
linear
influenza
b
r
valu
fig
within
run
variat
rang
cv
cv
high
control
cv
low
control
run
variat
cv
high
control
cv
low
control
tabl
limit
detect
limit
quantit
cutoff
posit
coincid
log
copiesml
analyt
specif
rsv
posit
predict
valu
neg
predict
valu
tabl
plot
linear
rsva
r
valu
plot
linear
rsvb
r
valu
fig
within
run
variat
rang
cv
cv
high
control
low
control
run
variat
cv
high
control
cv
low
control
tabl
limit
detect
limit
quantit
cutoff
posit
coincid
log
copiesml
crossreact
detect
three
assay
analysi
includ
sampl
patient
sampl
patient
influenza
viru
infect
sampl
patient
rsv
infect
tabl
show
demograph
clinic
characterist
patient
five
patient
coinfect
influenza
viru
rsv
median
number
sampl
per
patient
rang
influenza
rang
rsv
median
age
year
rang
patient
influenza
viru
infect
year
rang
rsv
infect
ten
patient
influenza
b
rsv
patient
coinfect
influenza
rsv
influenza
infect
detect
first
patient
seri
sampl
patient
rsv
detect
first
patient
virus
detect
simultan
initi
posit
sampl
patient
two
patient
influenza
influenza
b
coinfect
median
interv
collect
sampl
day
rang
day
sampl
influenza
b
viral
load
presenc
fever
e
cough
andor
f
nasal
congest
rsv
viral
load
presenc
g
fever
h
cough
andor
nasal
congest
p
valu
mix
linear
regress
model
p
p
p
viral
load
log
copiesml
dot
line
repres
lower
limit
quantif
assay
http
viral
respiratori
load
digit
pcr
initi
posit
biofir
filmarray
analysi
establish
limit
quantif
dpcr
consid
neg
influenza
influenza
b
rsv
correspond
sampl
obtain
antivir
treatment
complet
sampl
includ
valid
specif
influenza
influenza
b
rsv
clinic
sensit
influenza
influenza
b
rsv
viral
load
significantli
higher
patient
fever
cough
nasal
congest
patient
asymptomat
influenza
p
influenza
b
p
rsv
p
fig
infect
viral
load
patient
signssymptom
higher
signsymptom
fig
differ
signific
patient
influenza
p
influenza
b
p
rsv
p
infect
fever
associ
higher
viral
load
patient
influenza
infect
p
influenza
b
infect
fig
viral
load
patient
rsv
significantli
higher
febril
patient
year
age
p
differ
signific
older
patient
fig
patient
cough
significantli
higher
viral
load
signssymptom
irrespect
age
viru
type
fig
nasal
congest
significantli
associ
higher
viral
influenza
influenza
b
patient
year
age
nasal
congest
rsv
infect
significantli
higher
viral
load
compar
report
symptom
fig
common
virus
associ
influenza
rsv
rhinoviru
enteroviru
follow
coronaviru
parainfluenza
type
oxygen
requir
intens
care
unit
icu
admiss
number
death
differ
patient
singl
infect
coinfect
twentysix
patient
absolut
lymphocyt
count
less
time
diagnosi
fourteen
alc
less
sever
lymphopenia
alc
viral
load
significantli
correl
alc
patient
influenza
rsv
infect
fig
regardless
age
alc
also
associ
presenc
clinic
symptom
patient
influenza
influenza
b
rsv
infect
fig
lower
respiratori
tract
infect
lrti
develop
patient
influenza
b
rsv
infect
patient
requir
oxygen
admiss
influenza
b
rsv
infect
patient
influenza
b
rsv
infect
admit
icu
initi
viral
load
significantli
higher
patient
subgroup
compar
clinic
complic
tabl
two
patient
die
relat
rsv
infect
alc
develop
lrti
icu
time
death
univari
multivari
analys
includ
age
initi
viral
load
alc
covari
reveal
signific
associ
clinic
complic
tabl
addit
initi
viral
load
initi
alc
significantli
associ
consid
complic
togeth
fig
patient
influenza
infect
treat
oseltamivir
within
h
diagnosi
influenza
viral
load
receiv
treatment
significantli
lower
patient
influenza
p
influenza
b
p
infect
fig
ribavirin
administ
patient
rsv
infect
patient
inhal
ribavirin
patient
receiv
intraven
ribavirin
sinc
patient
mechan
ventil
tabl
viral
load
significantli
reduc
p
fig
complet
treatment
develop
valid
two
dpcr
assay
quantit
detect
influenza
viru
sampl
patient
rsv
sampl
patient
respiratori
tract
sampl
patient
hematolog
malign
solid
tumor
scd
patient
influenza
viru
rsv
infect
viral
load
associ
symptom
infect
furthermor
patient
receiv
antivir
treatment
significantli
decreas
viral
load
complet
therapi
correl
viral
load
sever
infect
remain
controversi
respiratori
virus
rsv
viral
load
significantli
associ
sever
presenc
respiratori
ill
children
year
age
analysi
cycl
threshold
valu
diseas
sever
patient
fuller
et
al
show
rsv
infect
viral
load
associ
diseas
sever
patient
younger
year
age
devincenzo
et
al
report
patient
intub
rsvinduc
respiratori
distress
higher
viral
load
higher
viral
load
associ
longer
hospit
could
measur
viral
load
lower
respiratori
tract
sampl
studi
howev
studi
show
viral
load
upper
lower
respiratori
tract
strongli
correl
measur
time
autopsi
studi
patient
fatal
rsv
ltri
viral
antigen
extens
present
lung
tissu
point
possibl
associ
viral
load
rsv
diseas
sever
howev
mani
studi
found
associ
gerna
et
al
report
direct
relationship
viral
load
clinic
symptom
patient
cohort
viral
load
associ
increas
risk
develop
bronchiol
find
previou
studi
associ
influenza
viral
load
diseas
sever
case
rsv
inconsist
studi
report
higher
viral
load
sever
viral
diseas
wherea
other
show
associ
wherea
other
report
associ
viral
coinfect
increas
decreas
diseas
sever
studi
find
signific
differ
viral
load
signssymptom
patient
viral
coinfect
versu
singl
infect
presenc
one
virus
impact
rsv
influenza
viral
load
pinki
et
al
show
fastgrow
virus
impair
replic
remain
virus
coinfect
wherea
slowgrow
virus
inhibit
presenc
virus
mechan
viral
competit
coinfect
might
explain
discrep
among
studi
anoth
studi
show
relationship
viral
load
multipl
viru
infect
viru
specif
limit
sampl
size
studi
allow
us
explor
viral
load
relat
differ
viru
might
explain
see
overal
chang
influenza
rsv
viral
load
case
viral
coinfect
lymphocyt
play
import
role
viral
respiratori
infect
alc
count
significantli
associ
increas
risk
progress
lrti
addit
patient
receiv
tcell
therapi
decreas
viral
load
viral
clearanc
resolut
clinic
symptom
although
symptomat
patient
lower
lymphocyt
count
asymptomat
patient
differ
signific
age
viru
associ
viral
load
therapeut
respons
seen
studi
preced
literatur
reduct
influenza
rsv
viral
load
use
differ
treatment
report
sever
anim
model
howev
studi
report
reduct
viral
load
treatment
associ
clinic
improv
human
particularli
children
high
risk
sever
infect
clinic
trial
adult
experiment
infect
rsv
show
reduct
viral
load
treatment
khanna
et
al
report
decreas
log
copiesml
rsv
load
adult
patient
hematolog
malign
within
day
initi
treatment
sever
case
report
case
seri
describ
role
oseltamivir
decreas
viral
load
respiratori
secret
signific
reduct
viral
load
influenza
viru
rsv
seen
studi
agre
studi
studi
relev
studi
previous
publish
use
dpcr
determin
viral
load
rsv
influenza
viru
pediatr
patient
hematolog
malign
solid
tumor
scd
assay
report
date
perform
use
realtim
pcr
dpcr
provid
advantag
endpoint
quantit
without
need
calibr
curv
improv
precis
reduc
likelihood
quantit
bia
base
amplif
effici
inhibit
sampl
initi
posit
biofir
neg
dpcr
sampl
collect
complet
antivir
treatment
might
anticip
due
subsampl
error
patient
low
viral
load
due
degre
sampl
degrad
similarli
low
load
sampl
near
assay
lod
result
agreement
previou
work
group
other
cytomegaloviru
show
although
dpcr
exhibit
increas
precis
qpcr
higher
viral
load
diminish
sensit
seen
sampl
low
viral
load
valu
potenti
attribut
reduc
input
sampl
volum
dpcr
system
studi
limit
sampl
size
patient
select
basi
avail
sampl
previous
test
posit
either
influenza
viru
rsv
henc
time
acquir
second
subsequ
sampl
respect
clinic
diseas
treatment
vari
among
patient
volum
retriev
nasal
wash
collect
clinic
inform
obtain
retrospect
chart
review
given
lack
commerci
avail
quantit
standard
difficult
develop
quantit
real
time
pcr
method
therefor
develop
real
time
assay
perform
direct
comparison
quantif
realtim
method
dpcr
rather
sought
develop
valid
digit
pcr
assay
perform
well
correl
clinic
diseas
use
monitor
respons
antivir
therapi
highlight
studi
patient
cohort
immunocompromis
repres
popul
respiratori
infect
sever
could
therefor
potenti
benefit
reliabl
measur
viral
load
found
rsv
viral
load
correl
presenc
clinic
symptom
patient
year
age
wherea
influenza
viral
load
associ
presenc
clinic
symptom
irrespect
age
patient
receiv
antivir
agent
signific
reduct
viral
load
influenza
viru
rsv
complet
therapi
digit
pcr
offer
effect
method
monitor
efficaci
antivir
treatment
respiratori
tract
infect
immunocompromis
host
potenti
aid
decis
regard
therapi
isol
largescal
prospect
studi
need
explor
potenti
benefit
dpcrbase
method
risk
stratif
impact
patient
manag
